Key facts
- It has raised $533.1M across 18 recorded rounds; the latest was Early Stage VC ($35.0M) in Mar 2024.
- Notable investors include Matter (Consulting Services (B2B)), Global Alternative Investment Management, Wicklow Capital, V. Gastevich Investments, Artemis Growth Partners — 12 tracked in total.
- PharmaCann has filed 21 Form Ds with the SEC since 2014, most recently Apr 2024 ($7.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 18 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for PharmaCann
Funding rounds
18 roundsAbout PharmaCann
Operator of a vertically integrated cannabis company intended to provide safe, reliable, and quality cannabis products to improve people's lives. The company specializes in cultivating, processing, and dispensing medicinal cannabis products and developing new forms and formulations of cannabinoid-based treatments for adult and pediatric patients, providing users with effective, affordable, and trusted cannabis products and services that help them live better lives.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Chicago, IL, United States
- Founded
- 2014
- Employees
- 3,100
- Website
- pharmacann.com/
- Ownership
- Privately Held (backing)
PharmaCann doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PharmaCann shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PharmaCann in its N-PORT filings yet. We sweep new filings monthly.